NIKKEI 225
40,074.69 +443.63 (+1.12%) HANG SENG
17,769.14 +50.53 (+0.29%) CRUDE OIL
82.87 -0.51 (-0.61%) GOLD FUTURES
2,335.30 -3.60 (-0.15%) DOW
39,275.65 +106.13 (+0.27%) Bitcoin GBP
49,062.16 -991.02 (-1.98%)
INZY Jul 2024 7.500 call
- GlobeNewswire
Inozyme Pharma Announces FDA Fast Track Designation for INZ-701 in ABCC6 Deficiency
Agency program will support and expedite clinical studies addressing severe unmet need in children with ABCC6 DeficiencyBOSTON, July 02, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to INZ-701 f
- Insider Monkey
Why Did Inozyme Pharma, Inc. (INZY) Get a Strong Buy Rating from Analysts?
We recently compiled a list of the 10 Best Biotech Penny Stocks to Buy Now. In this article, we are going to take a look at where Inozyme Pharma, Inc. (NASDAQ:INZY) stands against the other biotech penny stocks. Biotech Stocks in 2024: Growth Prospects, Key Players, and Investment Opportunities In 2024, the healthcare industry has […]
- GlobeNewswire
Inozyme Pharma Announces Presentation and Sponsored Symposium at the 11th International Conference on Children’s Bone Health (ICCBH)
Results from a radiographic study describing skeletal features of pediatric patients with ENPP1 Deficiency will be presentedBOSTON, June 21, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced a data presentation and sponsored symposium at the 11th International Conference on Children
